Additionally, a CCK8 experiment conducted by us showed that, over time, the viability of USP15-knockdown Huh-7 and HCC-LM3 cells treated with the same concentration of lenvatinib was lower than that of wild-type HCC cells. This evidence concerns the gene USP15 and hepatocellular carcinoma.